Publication | Open Access
Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC)
54
Citations
50
References
2017
Year
ImmunologyImmunotherapeuticsChemical BiologyImmunotherapySynthetic ImmunologyMedicinal ChemistryImmunochemistryAntibody EngineeringNext Generation MaleimideThiomab™ AntibodyBioconjugationAntibody ScreeningPharmacologyNext Generation MaleimidesBiomolecular EngineeringDrug TargetingNatural SciencesProtein EngineeringThiomab™ Antibody TechnologyMedicine
Conjugation of next generation maleimides to engineered cysteines in a THIOMAB™ antibody delivers a highly stable and potent THIOMAB™ antibody-drug conjugate.
| Year | Citations | |
|---|---|---|
Page 1
Page 1